EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC 4.0

Statistical properties of items and summary scores from the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE ® ) in a diverse cancer sample

Carolyn Mead-Harvey, Ethan Basch iD, Lauren J Rogak iD, Blake T Langlais, Gita Thanarajasingam, Brenda F Ginos, Minji K Lee, Claire Yee, Sandra A Mitchell, Lori M Minasian, Tito R Mendoza, Antonia V Bennett iD und 3 weitere

Clinical Trials · 2025

DOI: 10.1177/17407745241286065 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Clinical Trials, 2025. Verfasst von Carolyn Mead-Harvey und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Quantitative Health Sciences, Mayo Clinic, Scottsdale, AZ, USA. Hauptthemen laut MEDLINE: Antineoplastic Agents, Drug-Related Side Effects and Adverse Reactions, Neoplasms, Patient Reported Outcome Measures. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, Cancer Moonshot, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Aims: The Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE ® ) was developed to capture symptomatic adverse events from the patient perspective. We aim to describe statistical properties of PRO-CTCAE items and summary scores and to provide evidence for recommendations regarding PRO-CTCAE administration and reporting.

Methods

Using data from the PRO-CTCAE validation study (NCT02158637), prevalence, means, and standard deviations of PRO-CTCAE items, composite scores, and mean and maximum scores across attributes (frequency, severity, and/or interference) of symptomatic adverse events were calculated. For each adverse event, correlations and agreement between attributes, correlations between attributes and composite scores, and correlations between composite, mean, and maximum scores were estimated.

Results

PRO-CTCAE items were completed by 899 patients with various cancer types. Most patients reported experiencing one or more adverse events, with the most prevalent being fatigue (87.7%), sad/unhappy feelings (66.0%), anxiety (63.6%), pain (63.2%), insomnia (61.8%), and dry mouth (60.0%). Attributes were moderately to strongly correlated within an adverse event ( r = 0.53 to 0.77, all p < 0.001) but not fully concordant (κ weighted = 0.26 to 0.60, all p < 0.001), with interference demonstrating lowest mean scores and prevalence among attributes of the same adverse event. Attributes were moderately to strongly correlated with composite scores ( r = 0.67 to 0.97, all p < 0.001). Composite scores were moderately to strongly correlated with mean and maximum scores for the same adverse event ( r = 0.69 to 0.94, all p < 0.001). Correlations between composite scores of different adverse events varied widely ( r = 0.04 to 0.68) but were moderate to strong for conceptually related adverse events.

Conclusions

Results provide evidence for PRO-CTCAE administration and reporting recommendations that the full complement of attributes be administered for each adverse event, and that attributes as well as summary scores be reported.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsDrug-Related Side Effects and Adverse ReactionsNeoplasmsPatient Reported Outcome MeasuresAdultAgedFemaleHumansMaleMiddle Aged

Stichwörter der Autor:innen

PRO-CTCAE®Patient-reported outcomesadverse eventscancersymptomstolerability

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Department of Quantitative Health Sciences, Mayo Clinic, Scottsdale, AZ, USA.
  • UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA.
  • Division of Hematology, Mayo Clinic, Rochester, MN, USA.
  • Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.
  • National Cancer Institute, Rockville, MD, USA.
  • Memorial Sloan Kettering Cancer Center, New York, NY, USA.

ORCID-Profile: Ethan Basch, Lauren J Rogak, Antonia V Bennett, Amylou C Dueck

Förderung

  • NCI NIH HHS
  • Cancer Moonshot
  • National Cancer Institute

Zitieren

APA

Mead-Harvey, C., Basch, E., Rogak, L. J., Langlais, B. T., Thanarajasingam, G., Ginos, B. F., Lee, M. K., Yee, C., Mitchell, S. A., Minasian, L. M., Mendoza, T. R., Bennett, A. V., Schrag, D., Dueck, A. C., & Mazza, G. L. (2025). Statistical properties of items and summary scores from the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE ® ) in a diverse cancer sample. Clinical Trials. https://doi.org/10.1177/17407745241286065

Vancouver

Mead-Harvey C, Basch E, Rogak LJ, Langlais BT, Thanarajasingam G, Ginos BF, et al. Statistical properties of items and summary scores from the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE ® ) in a diverse cancer sample. Clinical Trials. 2025. doi:10.1177/17407745241286065

BibTeX
@article{MeadHarvey2025,
  author = {Mead-Harvey, Carolyn and Basch, Ethan and Rogak, Lauren J and Langlais, Blake T and Thanarajasingam, Gita and Ginos, Brenda F and Lee, Minji K and Yee, Claire and Mitchell, Sandra A and Minasian, Lori M and Mendoza, Tito R and Bennett, Antonia V and Schrag, Deborah and Dueck, Amylou C and Mazza, Gina L},
  title = {Statistical properties of items and summary scores from the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE ® ) in a diverse cancer sample},
  journal = {Clinical Trials},
  year = {2025},
  doi = {10.1177/17407745241286065}
}
Kostenlos starten →